Richard is the CCO at Proteome Sciences and has over 30 years’ experience working in the proteomics and biotechnology sectors. Since joining Proteome Sciences in 2017 he has focused on leading the Company’s marketing and commercialisation strategy to offer clients a flexible, high quality service in our CRO business.
Dr. Ginette Serrero is Chief Executive Officer of Precision Antibody, a custom antibody development company, expert in the design, development, characterization and production of monoclonal antibodies for the treatment and diagnosis of human diseases. She draws on biotech management and research expertise in Oncology and biomarker discovery to guide the company's strategy in both the service division and R&D department for the development of biological targeted therapies with companion tissue and serum diagnostics for breast cancer. Her laboratory discovered Progranulin (GP88) as a marker of recurrence, drug resistance and tumor aggressiveness for several cancers including breast and lung cancer. This led to the development of two companion diagnostics that have been clinically validated for disease prognosis and monitoring of breast and lung cancer patients. She is a trained Biochemist with expertise in target discovery, Pharmaceutical Sciences and Oncology. She is Adjunct Professor at the University of Maryland Greenebaum Comprehensive Cancer Center.
She is inventor on several worldwide patents for targets in Oncology and authored 100 peer-reviewed scientific publications and reviews.
Rakesh Dixit is a President & CEO, BIONAVIGEN, LLC, a biopharmaceutical virtual drug development company specializing in advising and consulting for all aspects of drug development, including discovery, preclinical development, CMC, translational sciences, clinical development and regulatory filing. Accomplished executive, inventor, and scientist with over 30 years of success with top biotechnology and pharmaceutical companies, including Merck, Johnson & Johnson, Medimmune, AstraZeneca.
Collin is a Scientist at EpigenDx in product and business development. He graduated from the Pennsylvania State University in 2023 with his Ph.D. in Plant Biology with a focus in genetics, specifically in the accumulation and biogenesis of microRNAs and secondary small interfering RNAs.
Dr. Borriello is Harvard Trained Pathologist having trained at the Brigham and Women’s Hospital in the division of immunology where he worked with Arlene Sharpe and Gordon Freeman on the B7-CD28 pathway; co-authoring several pivotal papers in the costimulatory field. He obtained his MD, PhD degrees at the Albert Einstein College of Medicine in NYC where he also worked with Dr. Stanley Nathenson on structure-function relationships in the MHC Class I surface antigens. Dr. Borriello transitioned from academic life to the pharmaceutical/financial sectors in 1999 and has been a pharma business development professional since 2006. In 2016, he was the head of search and evaluation at Baxalta across multiple therapeutic areas until the Shire acquisition, after which he left to found Alloplex Biotherapeutics in pursuit of an idea of his own invention in tumor immunology. He currently lives with his wife and daughter in the Boston area.
Christopher Garris is an Assistant professor at the Massachusetts General Hospital. By monitoring key hallmarks of anti-tumor immune function, we have developed novel platforms for combination immunotherapy selection in the re-programming of myeloid cells towards anti-tumor phenotypes.
